Synapse - Works

Results (5608)

Responses and durability in NSCLC treated with pegilodecakin and anti-PD-1

Meeting Abstract

Garon, E. B.; Schneider, J. G.; Wong, D. J. L.; Aljumaily, R.; Korn, W. M.; Infante, J. R.; Patel, M. R.; Autio, K. A.; Papadopoulos, K. P.; Naing, A.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Single-center analysis of 109 patients (pts) with metastatic chromophobe renal cell carcinoma (ChRCC): Differences in outcomes by histologic variant

Meeting Abstract

Ged, Y.; Knezevic, A.; Chen, Y.; Redzematovic, A.; Carlo, M. I.; Lee, C. H.; Feldman, D. R.; Patil, S.; Motzer, R. J.; Voss, M. H.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts)

Meeting Abstract

Funt, S.; McHugh, D. J.; Tsai, S.; O'Donnell, D.; Knezevic, A.; Patil, S.; Silber, D.; Reuter, V. E.; Sheinfeld, J.; Carver, B. S.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial

Meeting Abstract

Fradet, Y.; Bellmunt, J.; De Wit, R.; Vaughn, D. J.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203)

Meeting Abstract

Feldman, D. R.; Feuilly, M.; Meng, J.; Lister, J.; Marteau, F.; Morris, M. J.; George, D. J.; Choueiri, T. K.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC)

Meeting Abstract

Dos Santos Fernandes, G.; Chatila, W. K.; Yaeger, R.; Mendelsohn, R. B.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Lagunes, D. R.; Diaz, L. A.; Shia, J.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Hu, J.; Srinivas, S.; Stadler, W. M.; Costello, B. A.; Appleman, L. J.; Milowsky, M. I.; Patil, S.; Bromberg, M.; Nolan, P.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Escudier, B.; Motzer, R. J.; Rini, B. I.; Powles, T.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Gurney, H.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Emergency department (ED) presenting symptom clusters for chemotherapy patients

Meeting Abstract

Daly, R. M.; Nicholas, K.; Gorenshteyn, D.; Sokolowski, S.; Gazit, L.; Adams, L.; Matays, J.; Katzen, L. L.; Chiu, O. O.; Xiao, H.; more...
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save

Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203)

Meeting Abstract

Chen, R. C.; Feuilly, M.; Meng, J.; Lister, J.; Marteau, F.; Morris, M. J.; George, D. J.; Choueiri, T. K.
Journal of Clinical Oncology (2018)

Fulltext@MSK | Save